

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) A purified ~~Purified~~ natural or synthetic polypeptide comprising amino acid sequence SEQ ID NO: 1:

Met	Ala	Gly	Glu	Leu	Thr	Pro	Glu	Glu	Glu	10
Ala	Gln	Tyr	Lys	Lys	Ala	Phe	Ser	Ala	Val	20
Asp	Thr	Asp	Gly	Asn	Gly	Thr	Ile	Asn	Ala	30
Gln	Glu	Leu	Gly	Ala	Ala	Leu	Lys	Ala	Thr	40
Gly	Lys	Asn	Leu	Ser	Glu	Ala	Gln	Leu	Arg	50
Lys	Leu	Ile	Ser	Glu	Val	Asp	Ser	Asp	Gly	60
Asp	Gly	Glu	Ile	Ser	Phe	Gln	Glu	Phe	Leu	70
Thr	Ala	Ala	Arg	Lys	Ala	Arg	Ala	Gly	Leu	80
Glu	Asp	Leu	Gln	Val	Ala	Phe	Arg	Ala	Phe	90
Asp	Gln	Asp	Gly	Asp	Gly	His	Ile	Thr	Val	100
Asp	Glu	Leu	Arg	Arg	Ala	Met	Ala	Gly	Leu	110
Gly	Gln	Pro	Leu	Pro	Gln	Glu	Glu	Leu	Asp	120
Ala	Met	Ile	Arg	Glu	Ala	Asp	Val	Asp	Gln	130
Asp	Gly	Arg	Val	Asn	Tyr	Glu	Glu	Phe	Ala	140
Arg	Met	Leu	Ala	Gln	Glu					146

Claim 2. (Currently Amended) The polypeptide ~~Polypeptide~~ according to claim 1, wherein it is purified from animals.

Claim 3. (Currently Amended) ~~The polypeptide~~ Polypeptide according to claim 1, wherein it is purified from the skin of mammals.

Claim 4. (Currently Amended) ~~The polypeptide~~ Polypeptide according to claim 1, wherein it is purified from cultured or non-cultured human skin.

Claim 5. (Currently Amended) ~~The polypeptide~~ Polypeptide according to claim 1, wherein it is purified from the human epidermis.

Claim 6. (Currently Amended) ~~Natural or synthetic~~ A synthetic polypeptide whose sequence consists of ~~in part comprises~~ the sequence of polypeptide as described in claim 1.

Claim 7. (Currently Amended) ~~The polypeptide~~ Polypeptide according to claim 1, wherein it has a theoretical isoelectric point between 1 and 6.

Claim 8. (Currently Amended) ~~The polypeptide~~ Polypeptide according to claim 1, wherein it has a theoretical molecular weight of between 13 and 17 kilodaltons (kD).

Claim 9. (Currently Amended) A mixture ~~Mixture~~ of polypeptides obtained from the proteolysis of polypeptide as described in claim 1:

Claim 10. (Currently Amended) The polypeptide ~~Polypeptide~~ according to claim 1, wherein ~~in its~~ a primary sequence of the polypeptide, it has at least one ~~on~~ calcium-fixing site.

Claim 11. (Currently Amended) The polypeptide ~~Polypeptide~~ according to claim 1, wherein it fixes calcium.

Claim 12. (Currently Amended) A composition ~~Composition~~ comprising in a physiologically acceptable medium an ~~effective amount~~ amount effective to regulate the impairments of normal or pathological epidermal proliferation or differentiation of at least one polypeptide as defined in claim 1.

Claim 13. (Currently Amended) A composition ~~Composition~~ intended to regulate the impairments of normal or pathological epidermal proliferation or differentiation ~~epidermal, normal or pathological proliferation or differentiation~~, comprising, in a cosmetically acceptable medium, an effective amount of at least one polypeptide as defined in claim 1.

Claim 14. (Currently Amended) A composition ~~Composition~~ for treating dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyoses, or neoplasias, comprising in a physiologically acceptable medium, an effective amount of at least one polypeptide as defined in claim 1.

Claim 15. (Currently Amended) The composition ~~Composition~~ according to claim 12, which is intended for cosmetic or pharmaceutical application.

Claim 16. (Previously Presented) A method for the treatment of dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyoses, or neoplasias, comprising administering an effective amount of at least one polypeptide according to claim 1 to a patient in need of such treatment.

Claim 17. (Previously Presented) A method for regulating transglutaminases comprising administering an effective amount of at least one polypeptide according to claim 1 to a patient in need of such regulation.

Claim 18. (Previously Presented) The method according to claim 17, wherein the polypeptide or the composition is intended to regulate transglutaminase 3.

Claim 19. (Previously Presented) The composition according to claim 12, wherein the polypeptide or the composition is intended to regulate the formation of the corneal layer of the epidermis.

Claim 20. (Previously Presented) A method for treating dry skin, hyperkeratosis, parakeratosis, psoriasis, ichthyoses, neoplasias, wherein a cosmetic

composition as described in claim 12 is applied on the skin of the subject to be treated.

Claim 21. (Withdrawn) Isolated deoxyribonucleic acid fragment that codes for the polypeptide as defined in claim 1.

Claim 22. (Withdrawn) Isolated deoxyribonucleic acid fragment that comprises at least the nucleotide sequence that codes SEQ ID NO: 2 below:

AATTCCCGGA	TCCCTGCGGC	TGCCTGCACT	CTGGACCACG	40
AGCTCTGAGA	GCAGCAGGTT	GAGGGCCGGT	GGGCAGCAGC	80
TCGGAGGCTC	CGCGAGGTGC	AGGAGACGCA	GGCATGGCCG	120
GTGAGCTGAC	TCCTGAGGAG	GAGGCCCACT	ACAAAAAGGC	160
TTTCTCCGCG	GTTGACACGG	ATGGAAACGG	CACCATCAAT	200
GCCCAGGAGC	TGGGCGCGGC	GCTGAAGGCC	ACGGCAAGA	240
ACCTCTCGGA	GGCCCAGCTA	AGGAAACTCA	TCTCCGAGGT	280
TGACAGCGAC	GGCGACGGCG	AAATCAGCTT	CCAGGAGTTC	320
CTGACGGCGG	CAAGGAAGGC	CAGGGCCGGC	CTGGAGGACC	360
TGCAGGTCGC	CTTCCGCGCC	TTCGACCAGG	ATGGCGACGG	400
CCACATCACC	GTGGACGAGC	TCAGGCGGGC	CATGGCGGGG	440
CTGGGGCAGC	CGCTGCCGCA	GGAGGAGCTG	GACGCCATGA	480
TCCGCGAGGC	CGACGTGGAC	CAGGACGGGC	GGGTGAACTA	520
CGAGGAGTTC	GCGAGGATGC	TCGCCCAGGA	GTGAGGCTCC	560
CCGCCTGTGT	CCCCCTGGCT	GCGCTCTGAG	CCTTCAGGGC	600
CACCGCCCGC	TGCTGCTTTT	GTGCTGGGAC	TCTCCGGGGA	640

AACCTGGTCG	GTGGATGGGA	AACTGCCTCC	CCCTGGGAGG	680
AAGGCTTTGC	GCTCCGGGGC	CTGGATGCGG	CGCCCTCGGG	720
CCGCCTGCGA	GCCCCTCTCT	GCCTTCAGAC	CTTGGGCAGA	760
AGGAGGCCTC	CTTGGGCCTG	GTCCCCCTTT	GCCCTGCAGT	800
GGAATGAGGG	CCCCTTAACC	CCGCATTGAT	CTAAATAAAG	840
GACTGCCGAG	TTCCAAAA			858

Claim 23. (Withdrawn) Isolated deoxyribonucleic acid fragment that comprises all or part of the nucleotide sequence as described in claim 22.

Claim 24. (Withdrawn) Cosmetic or pharmaceutical composition, wherein it comprises, in a physiologically acceptable medium, at least one nucleotide sequence as described in claim 22.

Claim 25. (Previously Presented) A polypeptide or a mixture of polypeptides comprising at least one deoxyribonucleic acid sequence as described in claim 22.

Claim 26. (Original) Recombinant expression vector that contains all or part of the nucleotide sequence that codes SEQ ID NO: 2.

Claim 27. (Canceled)

Claim 28. (Original) Recombinant protein that is obtained by expression of an expression vector pGex-2T that contains all or part of the sequence that codes SEQ ID NO: 2.

Claim 29. (Previously Presented) A method for preparing a ribonucleic acid comprising using at least one deoxyribonucleic acid sequence as described in claim 22.

Claim 30. (Withdrawn) A method for preparing or purifying any molecule that can be bound specifically to at least one isolated purified polypeptide as described in claim 1 or to purified proteolysis fragments of said polypeptide or to a synthetic peptide of said polypeptide.

Claim 31. (Withdrawn) A method for preparing or purifying antiserums or specific monoclonal antibodies comprising using at least one isolated polypeptide or at least one of its proteolysis fragments or any synthetic peptide as described in claim 1.

Claim 32. (Withdrawn) Polyclonal or monoclonal antibodies, wherein said antibody recognizes specifically the polypeptide as described in claim 1.